Intersect ENT (Menlo Park, California), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, reported initial results from RESOLVE, a clinical study of the company's investigational steroid eluting implant designed to treat patients with recurrent sinus obstruction in the office setting. Results were presented at the annual American Rhinologic Society (Warwick, New York) meeting in Orlando.

Boston Scientific (Natick, Massachusetts) has initiated the REPRISE III clinical trial, a pivotal study to evaluate the safety and effectiveness of the Lotus Valve System in patients with severe aortic stenosis and who are considered to be at either high or extreme risk for surgical valve replacement. The Lotus Valve System is a transcatheter aortic valve replacement (TAVR) device that is both fully repositionable and retrievable prior to release.